ライフサイエンスコーパス: fosfomycin

1 s115, the molecular target of the antibiotic fosfomycin.

2 egio- and enantiomerically specific epoxide, fosfomycin.

3 turally occurring, broad-spectrum antibiotic fosfomycin.

4 and by exogenous ligands, such as substrate fosfomycin.

5 ber of bacteria have developed resistance to fosfomycin.

6 mydia rendering these organisms resistant to fosfomycin.

7 nthesis and is the target for the antibiotic fosfomycin.

8 (S)-2-hydroxypropylphosphonic acid (HPP) to fosfomycin.

9 amydial MurA was resistant to high levels of fosfomycin.

10 owth of C. trachomatis was also resistant to fosfomycin.

11 li O157:H7 and given either ciprofloxacin or fosfomycin.

12 d they were both inhibited by the antibiotic fosfomycin.

13 the primary site of action of the antibiotic fosfomycin.

14 e dependent on the presence of the substrate fosfomycin.

15 bserved reversible competitive inhibition by fosfomycin.

16 ly resistant to time-dependent inhibition by fosfomycin.

17 mides, aminoglycosides, chloramphenicol, and fosfomycin.

18 y the clinically used irreversible inhibitor fosfomycin.

19 d for the phosphonate-containing antibiotic, fosfomycin.

20 tall the oxirane "warhead" of the antibiotic fosfomycin.

21 s of host cells, and increased resistance to fosfomycin.

22 sphate (G3P), glucose-6-phosphate (G6P), and fosfomycin.

23 a coli host for responding to the antibiotic fosfomycin.

24 t step in the biosynthesis of the antibiotic fosfomycin.

25 ed synergy between ceftazidime-avibactam and fosfomycin.

26 -2-HPP in the biosynthesis of the antibiotic fosfomycin.

27 alcohol of (S)-2-HPP to the epoxide ring of fosfomycin.

28 ynthesis of the clinically useful antibiotic fosfomycin.

29 )-HPP) in the biosynthesis of the antibiotic fosfomycin.

30 bout inhibition/alkylation by the antibiotic fosfomycin.

31 S-HPP) in the biosynthesis of the antibiotic fosfomycin.

32 The fosfomycin (1) resistance proteins FosA and FosX in path

33 zyme conferring resistance to the antibiotic fosfomycin [(1R,2S)-1,2-epoxypropylphosphonic acid] orig

34 opyl-1-phosphonate (S-HPP) to the antibiotic fosfomycin [(1R,2S)-epoxypropylphosphonate] in an unusua

35 Fosfomycin [(1R,2S)-epoxypropylphosphonic acid] is a sim

36 nt addition of glutathione to the antibiotic fosfomycin, (1R,2S)-epoxypropylphosphonic acid, renderin

37 X, catalyzes the hydration of the antibiotic fosfomycin, (1R,2S)-epoxypropylphosphonic acid.

38 resistance to the broad-spectrum antibiotic fosfomycin, (1R,2S)-epoxypropylphosphonic acid.

39 Treatment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours I

40 hanges due to treatment with the antibiotics fosfomycin (a cell-wall biosynthesis inhibitor) and chlo

41 Treatment with fosfomycin (a PG synthesis inhibitor) leads to lower inf

42 The last step of the biosynthesis of fosfomycin, a clinically useful antibiotic, is the conve

43 the epoxide ring closure of (S)-HPP to form fosfomycin, a clinically useful antibiotic.

44 previously been shown to cause resistance to fosfomycin, a potent antibiotic that specifically target

45 colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or merop

46 tudies and clinical use, the permeability of fosfomycin across the bacterial outer membrane is largel

47 closed enzyme conformation, with the Cys115-fosfomycin adduct buried in the active site.

48 alone and in combination with meropenem and fosfomycin against A. baumannii strains belonging to clo

49 Our findings corroborate that amikacin and fosfomycin alone efficiently reduced P. aeruginosa in tr

50 eruginosa concentrations versus amikacin and fosfomycin, amikacin, CONTROL, and fosfomycin groups (p

51 Fosfomycin, an epoxide, is a relatively poor drug becaus

52 r, cells lacking BSH are highly sensitive to fosfomycin, an epoxide-containing antibiotic detoxified

53 urred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparat

54 met in 36 of 48 patients (75.0%) assigned to fosfomycin and 30 of 46 patients (65.2%) assigned to cip

55 men), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with co

56 Several of these compounds, such as fosfomycin and bialaphos, figure prominently in human he

57 In patients assigned to fosfomycin and ciprofloxacin, microbiological cure at da

58 As a result, fosfomycin and D-cycloserine were added to the group of

59 al efficacy and safety of the combination of fosfomycin and imipenem as rescue therapy for MRSA infec

60 is the active site nucleophile alkylated by fosfomycin and implicated this residue in the formation

61 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given dapto

62 sed on available literature, the activity of fosfomycin and nitrofurantoin remain high for most cases

63 e expressed more by plasmids, in contrast to fosfomycin and peptide AMR expression by phages, thereby

64 MLS and sulfonamide) via plasmids or phages (fosfomycin and peptide), whereas others were disseminate

65 We report two cases cured with oral fosfomycin and provide a pharmacokinetic analysis of fos

66 as used to methylate the clinical antibiotic fosfomycin and the antimalaria clinical candidate fosmid

67 d to catalyze the epoxidation of ( S)-HPP to fosfomycin and the oxidation of ( R)-HPP to 2-oxopropylp

68 ction of P. aeruginosa isolates (n = 198) to fosfomycin and to compare testing agreement rates across

69 Amikacin, amikacin and fosfomycin, and amikacin and fosfomycin + IV meropenem e

70 esis of the antibiotics nisin, lacticin 481, fosfomycin, and bialaphos.

71 4 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving dap

72 ound to be associated with susceptibility to fosfomycin, and loss of this system or general inhibitio

73 (+), residues that furnish hydrogen bonds to fosfomycin, and residues located in a putative glutathio

74 aeruginosa pneumonia, resistant to amikacin, fosfomycin, and susceptible to meropenem.

75 e (PDC), and MurA with ceftazidime-avibactam-fosfomycin, antimicrobial susceptibility was restored am

76 Fosfomycin appears to achieve reasonable intraprostatic

77 ent) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicate

78 ma-imido)-triphosphate (AMPPNP), Mg(II), and fosfomycin, at 1.53 and 2.2 angstroms resolution, respec

79 d residues located in a putative glutathione/fosfomycin-binding site.

80 the enzyme that catalyzes the second step of fosfomycin biosynthesis in Streptomyces wedmorensis.

81 eport the crystal structure of FomA from the fosfomycin biosynthetic gene cluster of Streptomyces wed

82 n orientation that is different than that of fosfomycin bound to the related enzyme, FosA.

83 for substrate-free enzyme to 0.23 cm(-1) for fosfomycin-bound enzyme, 0.28 (1) cm(-1) for FosA with p

84 -lactams, including cefuroxime (CEF), and to fosfomycin but that resistant mutants arise due to gain-

85 (S)-2-hydroxypropylphosphonic acid (HPP) to fosfomycin by HPP epoxidase (HppE), which is a mononucle

86 sfomycin resistance protein FomA inactivates fosfomycin by phosphorylation of the phosphonate group o

87 in the molecular simulations, we found that fosfomycin can rapidly permeate the abundant Escherichia

88 lightly lower than that of the wild type but fosfomycin can still permeate.

89 accelerated by bound substrate and produces fosfomycin catalytically with a stoichiometry of unity.

90 age demonstrated that ciprofloxacin, but not fosfomycin, caused enhanced intraintestinal transfer of

91 Ciprofloxacin but not fosfomycin causes Shiga toxin-encoding bacteriophage ind

92 Thus, the cyclization of HPP to fosfomycin clearly represents an intriguing conversion b

93 Herein, ceftazidime-avibactam-fosfomycin combination therapy against MDR P. aeruginosa

94 rised 369 participants, of whom 178 received fosfomycin combination therapy and 191 received monother

95 analysis demonstrated an association between fosfomycin combination therapy and treatment success at

96 randomized controlled trials, which assessed fosfomycin combined with daptomycin or cloxacillin versu

97 We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-dow

98 The MurA-fosfomycin complex exists in the closed enzyme conformat

99 Only 1 patient had a mean prostatic fosfomycin concentration of <1 microg/g, whereas the maj

100 ansition zone [TZ] and peripheral zone [PZ]) fosfomycin concentrations using liquid chromatography-ta

101 eus (0.3mg dry weight analyzed) treated with fosfomycin, D-boroAla, D-cycloserine, and vancomycin.

102 lysis when exposed to low concentrations of fosfomycin, d-cycloserine, vancomycin, and nisin, indica

103 This study found that fosfomycin did not demonstrate noninferiority to compara

104 ith death in two-thirds of the mice, whereas fosfomycin did not.

105 ies within the zone of inhibition around the fosfomycin disk is occasionally observed upon susceptibi

106 ere randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participant

107 ss spectrometry, following a single 3-g oral fosfomycin dose within 17 hours of surgery.

108 EPR spectrum of oxidized iron-reconstituted fosfomycin epoxidase reveals resonances typical of S = (

109 med using a glucose-6-phosphate-supplemented fosfomycin Etest and Kirby-Bauer disk diffusion (DD) ass

110 ETEST fosfomycin (ETEST FO) clinical performance was evaluated

111 n and fosfomycin every 6 hours; amikacin and fosfomycin every 6 hours, with IV meropenem every 8 hour

112 alone every 8 hours; nebulized amikacin and fosfomycin every 6 hours; amikacin and fosfomycin every

113 nebulized amikacin every 6 hours; nebulized fosfomycin every 6 hours; IV meropenem alone every 8 hou

114 Whole cells treated with fosfomycin exhibited decreased peptidoglycan contributio

115 Here we assess three well known antibiotics, fosfomycin, flomoxef and amikacin, in combination as pot

116 ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with

117 115D mutant, showing an additive effect with fosfomycin for the inhibition of WT MurA.

118 xpression of the glpTQ genes, which leads to fosfomycin (FOS) resistance.

119 o ceftazidime/avibactam (CAT) and 5 (50%) to fosfomycin (FOS).

120 s (penicillin, cephalosporins, streptomycin, fosfomycin, gramicidin S, rapamycin, indolmycin, microci

121 switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral er

122 kacin and fosfomycin, amikacin, CONTROL, and fosfomycin groups (p < 0.05), without significant differ

123 Since the ring oxygen in fosfomycin has been shown in earlier feeding experiments

124 Fosfomycin has been shown to have a wide spectrum of act

125 Fosfomycin has reasonable in vitro and urinary activity

126 otherapy, we show that ceftazidime-avibactam-fosfomycin has the potential to offer infected patients

127 Although the addition of the substrate, fosfomycin, has no appreciable effect on the association

128 is showed a 91.8% posterior probability that fosfomycin improves treatment success at 8 weeks (median

129 t success was achieved after commencement of fosfomycin in conjunction with high-dose meropenem.

130 rulence factor, Hpt, also mediates uptake of fosfomycin in Listeria monocytogenes.

131 The role of adjunctive fosfomycin in Staphylococcus aureus bacteremia (SAB) rem

132 The final step in the biosynthesis of fosfomycin in Streptomyces wedmorensis is catalyzed by (

133 The most prescribed drugs were fosfomycin in SUS (44.0%), DR1/2 (41.4%), and fluoroquin

134 When SF2312 is combined with fosfomycin in the presence of glucose-6 phosphate, signi

135 These bacteria therefore seem resistant to fosfomycin in vitro, although they are in fact susceptib

136 resistance of the C115D and C115E mutants to fosfomycin inactivation.

137 ombination of polymyxin B with meropenem and fosfomycin inhibited the polymyxin B-resistant subpopula

138 The antibiotic fosfomycin inhibits bacterial cell wall biosynthesis by

139 f daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of d

140 oxide-containing phosphonate natural product fosfomycin is a broad-spectrum antibiotic used in the tr

141 Fosfomycin is a frequently prescribed drug in the treatm

142 Fosfomycin is a phosphonic acid derivative active agains

143 the mechanisms of inactivation are similar, fosfomycin is approximately 50 times more potent than te

144 thoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin is indicated for acute cystitis in adult wome

145 Fosfomycin is noninferior to ciprofloxacin as oral step-

146 Fosfomycin is produced by both the plant pathogen Pseudo

147 The last step of the biosynthesis of fosfomycin is the conversion of (S)-2-hydroxypropylphosp

148 Further complicating the utility of fosfomycin is the specified method for MIC determination

149 n, amikacin and fosfomycin, and amikacin and fosfomycin + IV meropenem effectively reduced P. aerugin

150 In particular, IV meropenem and amikacin and fosfomycin + IV meropenem groups presented lower P. aeru

151 off) = 5 s(-1)) that is slower than that for fosfomycin (k(off) = 30 s(-1)).

152 r that interacts strongly with the substrate fosfomycin (Kd = 17 microM) more weakly with the product

153 the 26 participants, mean plasma and urinary fosfomycin levels were 11.4 +/- 7.6 microg/mL and 571 +/

154 Mean overall prostate fosfomycin levels were 6.5 +/- 4.9 microg/g (range, 0.7-

155 Fosfomycin maintains activity against most Escherichia c

156 This finding suggests that fosfomycin may be considered for selected patients with

157 Adjunctive fosfomycin may improve early bacterial clearance and tre

158 ed in IV meropenem group versus amikacin and fosfomycin + meropenem (p = 0.004).

159 In conclusion, fosfomycin-nonsusceptible inner colony mutants can occur

160 ed to step-down treatment with once-daily 3g fosfomycin or twice-daily 0.5g ciprofloxacin for 10 days

161 ed to cycloserine and bacitracin, but not to fosfomycin or valinomycin; these drugs, like beta-lactam

162 Here, we investigate the fosfomycin permeability across the outer membrane of Gra

163 her, this work unravels molecular details of fosfomycin permeation through the outer membrane porin O

164 involved in biosynthesis of the antibiotics fosfomycin, phosphinothricin tripeptide, and dehydrophos

165 trofurantoin, trimethoprim-sulfamethoxazole, fosfomycin, pivmecillinam.

166 Fosfomycin plus imipenem was an effective and safe combi

167 in and provide a pharmacokinetic analysis of fosfomycin predose concentrations during treatment.

168 Daptomycin plus fosfomycin provided 12% higher rate of treatment success

169 e aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptom

170 ics of MurA inactivation by terreic acid and fosfomycin reflect the importance of noncovalent binding

171 of glutathione to carbon-1 of the antibiotic fosfomycin, rendering it ineffective as an antibacterial

172 and encoded for blaACT-15 beta-lactamase and fosfomycin resistance (fosA).

173 In addition, we assessed the presence of fosfomycin resistance genes from whole-genome sequencing

174 or bshA caused a 16- to 60-fold reduction in fosfomycin resistance in these S. aureus strains.

175 The fosfomycin resistance protein FomA inactivates fosfomyci

176 amily of amino acid kinases that include the fosfomycin resistance protein fomA, which deactivates th

177 The fosfomycin resistance protein FosA is a member of a dist

178 The fosfomycin resistance protein, FosA, catalyzes the Mn(2+

179 The fosfomycin resistance protein, FosX, catalyzes the hydra

180 Bacillus subtilis fosB(yndN) gene encodes a fosfomycin resistance protein.

181 te-binding site are conserved in the related fosfomycin resistance proteins FosB and FosX, whereas no

182 ioxygenase), and nucleophilic substitutions (fosfomycin resistance proteins).

183 or the ability of resulting clones to confer fosfomycin resistance to Escherichia coli were used to i

184 Moreover, fosfomycin resistance was imparted to the E. coli strain

185 nes: fosA, a locus associated with low level fosfomycin resistance, and tnpB transposase on IncFIB(K)

186 ich encodes a BSH-S-transferase that confers fosfomycin resistance, in several S. aureus strains, inc

187 B. anthracis prophage, encoding demonstrable fosfomycin resistance.

188 A fosfomycin-resistant C115E mutant with -1% activity of t

189 equally inhibit wild type (WT) MurA and the fosfomycin-resistant MurA C115D mutant, showing an addit

190 and 2 inhibited not only wild-type but also fosfomycin-resistant MurA in an unprecedented way.

191 ted that 2 is a potent inhibitor of MRSA and fosfomycin-resistant MurA, laying the foundation for the

192 nce to the oxirane or phosphonate oxygens of fosfomycin resulted in variants with very low or no acti

193 nt with a unique mechanism of action such as fosfomycin seems attractive.

194 sigma(W), and both fosB and sigW mutants are fosfomycin sensitive.

195 Administration of ceftazidime-avibactam and fosfomycin separately significantly increased CFUs, by a

196 s the excision of all, and ciprofloxacin and fosfomycin significantly promote the excision of a subse

197 high bacterial burden, ceftazidime-avibactam-fosfomycin significantly reduced the P. aeruginosa colon

198 Fosfomycin still bound to the active site of C115D MurA,

199 Fosfomycin still bound to the active site of C115D MurA,

200 improve its performance and robustness, the fosfomycin strip, an antibiotic gradient diffusion strip

201 o tigecycline and had very low resistance to fosfomycin, suggesting a potential for these as empiric

202 We evaluated fosfomycin susceptibility by multiple methods with 96 KP

203 carry high biological costs, we suggest that fosfomycin susceptibility of strains that generate inner

204 h microdilution may be a reliable method for fosfomycin susceptibility testing against P. aeruginosa

205 However, establishing accurate fosfomycin susceptibility testing for non-Escherichia co

206 products, including the approved antibiotic fosfomycin, the widely used herbicide phosphinothricin (

207 sistance against the Streptomyces antibiotic fosfomycin, these studies support the notion that sigma(

208 y FosA involves the attack by glutathione on fosfomycin to yield the product 1-(S-glutathionyl)-2-hyd

209 novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (

210 stals (100 mg twice daily for 5-7 days), and fosfomycin trometamol (3 g in a single dose) are all app

211 ticipants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an act

212 Fosfomycin-trometamol (FT) could be an alternative, but

213 Fosfomycin-trometamol has a reasonable effectiveness as

214 Fosfomycin-trometamol resulted in microbiological cure i

215 Fosfomycin-trometamol was used for a median short durati

216 Fosfomycin use is associated with more gastrointestinal

217 ording to EUCAST breakpoints for intravenous fosfomycin use, Enterobacterales and Staphylococcus spp.

218 thway of the clinically important antibiotic fosfomycin uses enzymes that catalyse reactions without

219 event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs

220 When fosfomycin was administered alone, the frequency of muta

221 Fosfomycin was associated with a significant reduction i

222 At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failu

223 e retention of the hydroxyl oxygen of HPP in fosfomycin was demonstrated.

224 Acquired resistance to fosfomycin was observed in 6 episodes.

225 Disk diffusion testing of fosfomycin was performed on 649 multidrug-resistant E. c

226 us, the combination of ceftazidime-avibactam-fosfomycin was superior to either drug alone.

227 c, resistances to colistin, tigecycline, and fosfomycin were also observed as a result of repeated, i

228 T(MSW) for meropenem and fosfomycin were also reduced.

229 ta-lactams, sulphonamides, tetracyclines and fosfomycin were identified.

230 resistance to the broad-spectrum antibiotic fosfomycin, which contains a phosphonate group.

231 target of the naturally occurring antibiotic fosfomycin, which covalently attaches to Cys115 in the a

232 Although fosfomycin, which is the only clinically used MurA-targe

233 hed antibiotic target since the discovery of fosfomycin, which specifically inhibits MurA by covalent

234 high intrinsic resistance to the antibiotic fosfomycin, which targets UDP-MurNAc de novo biosynthesi

235 tance was high; however, coadministration of fosfomycin with ceftazidime-avibactam yielded a lower fr

236 Combination of amikacin and fosfomycin with IV meropenem does not increase antipseud